SW · BMY.SW
Bristol-Myers Squibb Company
- Sector
- Healthcare · Medical - Pharmaceuticals
- Headquarters
- New York City, NY 10016
- Website
- bms.com
Price · as of 2024-12-31
$42.54
Market cap 70.7B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $0.00 | $16.70 | |||
| 2011 | $0.00 | $29.20 | |||
| 2012 | $0.00 | $0.00 | |||
| 2013 | $0.00 | $1.80 | |||
| 2014 | $48.59 | $41.80 | $4.40 | $0.00 | $5.10 |
| 2015 | $47.83 | $40.41 | $3.56 | $0.00 | $9.10 |
| 2016 | $43.88 | $46.16 | $12.27 | $0.00 | $52.80 |
| 2017 | $49.43 | $47.37 | $11.31 | $0.00 | $7.30 |
| 2018 | $41.97 | $47.79 | $31.79 | $0.00 | $39.40 |
| 2019 | $37.18 | $41.65 | $22.62 | $2.90 | $37.50 |
| 2020 | $38.64 | $39.58 | $622.36 | $0.00 | $0.00 |
| 2021 | $49.16 | $52.08 | $559.55 | $0.00 | $42.10 |
| 2022 | $51.08 | $53.23 | $209.19 | $0.00 | $17.80 |
| 2023 | $53.07 | $52.88 | $7.17 | $0.00 | $18.00 |
| 2024 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Bristol-Myers Squibb Company's (BMY.SW) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $42.54
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
- CEO
- Christopher S. Boerner
- Employees
- 34.1K
- Beta
- 0.29
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $42.54) − 1 = — (DCF, example).